Please login to the form below

Not currently logged in
Email:
Password:

Ilumya

This page shows the latest Ilumya news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

Latest news

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    Sun Pharma passes milestone with novel psoriasis drug approval. Ilumya will treat adults with a moderate-to-severe form of the skin condition. ... We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people

  • Archive listing

    Ilumya will treat adults with a moderate-to-severe form of the skin condition. .

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics